$1.18
-0.02[-1.67%]
At close: Apr 29
$1.18
0[0.00%]
After Hours: 6:03PM EDT
Aclaris Therapeutics
(NASDAQ:ACRS)Latest News for Aclaris Therapeutics Stock (NASDAQ:ACRS)
Aclaris Therapeutics Stock (NASDAQ: ACRS)
Categories: All
Wednesday, March 06, 2024
Tuesday, February 27, 2024
Monday, January 22, 2024
- Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst DowngradesVandana Singh - Jan 22, 2024, 2:37PM
- Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Jan 22, 2024, 1:08PM
- Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Jan 22, 2024, 8:21AM
- HC Wainwright & Co. Downgrades Aclaris Therapeutics to NeutralBenzinga Newsdesk - Jan 22, 2024, 7:14AM
Tuesday, January 16, 2024
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Jan 16, 2024, 12:31PM
- Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?Vandana Singh - Jan 16, 2024, 11:47AM
- Aclaris Therapeutics Announced That Douglas Manion Will Step Down As CEO, President And Board Member, Effective Immediately; The Company Has Appointed Neal Walker, Aclaris' Chairman As Interim CEOBenzinga Newsdesk - Jan 16, 2024, 7:10AM
Thursday, January 11, 2024
Wednesday, January 10, 2024
- Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data VariationsVandana Singh - Jan 10, 2024, 3:12PM
- Crude Oil Falls 1%; Amarin Shares Spike HigherAvi Kapoor - Jan 10, 2024, 2:16PM
- Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Jan 10, 2024, 1:06PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Jan 10, 2024, 12:31PM
- Nasdaq Gains 50 Points; US Crude Inventories Rise Last WeekAvi Kapoor - Jan 10, 2024, 12:04PM
- Aclaris Therapeutics Shares Fall On Mixed Results From Mid-Stage Eczema TrialVandana Singh - Jan 10, 2024, 11:39AM
- Dow Surges 100 Points; PriceSmart Earnings Top ViewsAvi Kapoor - Jan 10, 2024, 9:50AM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Jan 10, 2024, 8:05AM
- Aclaris Therapeutics shares are trading lower after the company's Phase 2B study of ATI-1777 2% QD was not statistically superior on the primary efficacy endpoint.Benzinga Newsdesk - Jan 10, 2024, 7:43AM
- Aclaris Therapeutics Says Phase 2B Study Of Ati-1777 2% QD For Atopic Dermatitis Was Not Statistically Superior On The Primary Efficacy Endpoint; (68.3% Compared to 59.5% in Vehicle, p=0.086)Benzinga Newsdesk - Jan 10, 2024, 7:04AM
Friday, December 29, 2023
Wednesday, December 20, 2023
Tuesday, December 19, 2023
- Aclaris Therapeutics Says Taking Steps To Reduce Spending And Streamline Organization With Discontinuation Of Development Of ATI-450 For Immuno-inflammatory Disease IndicationsBenzinga Newsdesk - Dec 19, 2023, 4:08PM
- Aclaris Therapeutics Plans To Reduce Its Workforce By Approximately 46%Benzinga Newsdesk - Dec 19, 2023, 4:06PM
Monday, December 18, 2023
- Breaking Down Aclaris Therapeutics: 6 Analysts Share Their ViewsBenzinga Insights - Dec 18, 2023, 4:01PM
- Aclaris Therapeutics Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)Benzinga Insights - Dec 18, 2023, 10:39AM
- Stifel Maintains Hold on Aclaris Therapeutics, Lowers Price Target to $1Benzinga Newsdesk - Dec 18, 2023, 9:22AM
Wednesday, December 06, 2023
Tuesday, December 05, 2023
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Dec 5, 2023, 4:31PM
- Aclaris Therapeutics Announces Exclusive Patent License Agreement With Sun Pharma For Rights Of Deuruxolitinib; Agreement Includes Upfront Payment Of $15M Plus Milestones And RoyaltiesBenzinga Newsdesk - Dec 5, 2023, 4:02PM
Tuesday, November 14, 2023
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Nov 14, 2023, 12:31PM
- HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $9Benzinga Newsdesk - Nov 14, 2023, 9:32AM
- The Latest Analyst Ratings for Aclaris TherapeuticsBenzinga Insights - Nov 14, 2023, 8:00AM
- Cantor Fitzgerald Downgrades Aclaris Therapeutics to NeutralBenzinga Newsdesk - Nov 14, 2023, 4:10AM
Monday, November 13, 2023
- Crude Oil Gains Over 1%; US Budget Deficit Narrows For OctoberLisa Levin - Nov 13, 2023, 2:35PM
- Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Nov 13, 2023, 1:08PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Nov 13, 2023, 12:31PM
- Dow Surges 100 Points; Tenax Therapeutics Shares Spike HigherLisa Levin - Nov 13, 2023, 12:03PM
- Stifel Downgrades Aclaris Therapeutics to Hold, Lowers Price Target to $2Benzinga Newsdesk - Nov 13, 2023, 12:00PM
- William Blair Downgrades Aclaris Therapeutics to Market PerformBenzinga Newsdesk - Nov 13, 2023, 11:55AM
- Why Is Arthritis-Focused Aclaris Therapeutics Stock Nosediving Today?Vandana Singh - Nov 13, 2023, 9:51AM
- US Stocks Fall; Tyson Foods Posts Upbeat EarningsLisa Levin - Nov 13, 2023, 9:47AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Nov 13, 2023, 8:06AM
- Aclaris Announces Topline Results From 12-Week Phase 2b Trial Of Oral Zunsemetinib For Moderate To Severe Rheumatoid Arthritis; Study Did Not Meet Primary Or Secondary Efficacy Endpoints, Efficacy Results Do Not Support Further Development Of ZunsemetinibBenzinga Newsdesk - Nov 13, 2023, 7:10AM